Smart and sensing robotic system for endovascular interventions with haptic feed...
Smart and sensing robotic system for endovascular interventions with haptic feedback
"UAB ""Inovatyvi medicina"" has developed an innovative design of endovascular robotic system HAPGuide. This SMART and SENSING technology allows to perform endovascular procedures without medical personnel being exposed to harmful...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto HAPGuide
Duración del proyecto: 7 meses
Fecha Inicio: 2019-05-20
Fecha Fin: 2019-12-31
Líder del proyecto
UAB INOVATYVI MEDICINA
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"UAB ""Inovatyvi medicina"" has developed an innovative design of endovascular robotic system HAPGuide. This SMART and SENSING technology allows to perform endovascular procedures without medical personnel being exposed to harmful X-rays. HAPGuide solves the main issues of existing robotic systems and opens up possibilities for safer, faster and more effective endovascular interventions in EU and Worldwide. In comparison to existing systems (with only visual feedback and videogame like control) the main HAPGuide advantage is the haptic feedback and traditional control of endovascular instruments using fine-tuned surgeons’ perception-action-visualization abilities. Future developments involve HAPGuide use in telemedicine and partially automated functions via machine learning. Our system is designed to use all standard endovascular instruments and avoids the need of expensive catheters dedicated for the system. The primary target market of HAPGuide is cath labs performing percutaneous coronary interventions and peripheral vascular procedures in EU and US (more than 5.6 mln. procedures annually). The estimated market potential of HAPGuide robotic system in primary worldwide market exceeds €4 billion. The secondary target market would involve neurointerventional procedures while in the long-run expansion to telerobotics will create new market opportunities. Our revenue model involves four main components: 1) durable robotic HAPGuide system; 2) single use cassette; 3) annual service of the system; 4) HAPLearn training software. A multidisciplinary team with vast experience in medical sciences, medical device development, robotics, mechanical and electronic engineering, product design, commercialisation and business development has joined forces for the implementation of HAPGuide project aiming to bring the technology to clinical practice for benefit of patients, physicians and hospitals and exploit this €4 billion niche market commercial opportunity."